In:
Science Translational Medicine, American Association for the Advancement of Science (AAAS), Vol. 15, No. 706 ( 2023-07-26)
Abstract:
Patient-derived organoids can capture the heterogeneity of cancer pathology to thereby inform precision treatment strategies. Ji et al. present 65 patient-derived cancer organoids comprising four major types of liver cancer, whose similarity to their parental tumors was shown by histology plus comprehensive multiomics assessment. Further analysis revealed a lipid metabolism–dependent cluster of liver cancers mediated by glucose-6-phosphate dehydrogenase, and pharmacological screening of the organoids detected a possible synergistic effect of mTOR inhibitor temsirolimus with levatinib, which the authors validated in in vivo models. These studies demonstrate how this organoid bank could be mined to improve liver cancer therapy. —Catherine Charneski
Type of Medium:
Online Resource
ISSN:
1946-6234
,
1946-6242
DOI:
10.1126/scitranslmed.adg3358
Language:
English
Publisher:
American Association for the Advancement of Science (AAAS)
Publication Date:
2023
detail.hit.zdb_id:
2518839-2
detail.hit.zdb_id:
2518854-9